Trials / Completed
CompletedNCT04422509
Lanadelumab for Treatment of COVID-19 Disease
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Radboud University Medical Center · Academic / Other
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
So far little is very few drugs have demonstrated positive results for treatment of COVID19. Recently the researchers have shown that the use of icatibant in COVID-19 results in a potent decrease in oxygen use. Yet the effect of the three dosages as according to the label dose was insufficient to maintain the clinical improvement in a small group of patients. The researchers argue that with the use of lanadelumab a more lasting effect can be reached due to its longer half life.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | lanadelumab | single dose, or two doses administered iv |
| OTHER | regular care | no lanadelumab administration, treated according to regular care |
Timeline
- Start date
- 2020-10-30
- Primary completion
- 2021-02-25
- Completion
- 2021-04-30
- First posted
- 2020-06-09
- Last updated
- 2021-07-13
Locations
4 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT04422509. Inclusion in this directory is not an endorsement.